Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739660 | 0.77 | KIF11 (0.44) | ARALDH1A1HPGDSMN1; SMN2NPSR1 | |
| SCHEMBL22854087 | 0.74 | PPARD (0.41) | PPARDHTTALDH1A1TSHRNPC1 | |
| SCHEMBL18935708 | 0.74 | AR (0.39) | ARCHEK1 | |
| SCHEMBL13335925 | 0.72 | POLB (0.40) | PPARDHTTALDH1A1TSHRNPC1 | |
| SCHEMBL18745830 | 0.71 | AR (0.40) | ARSMN1; SMN2CHEK1NPC1RAB9A | |
| SCHEMBL18503874 | 0.70 | PPARD (0.44) | PPARDHTTALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL19251124 | 0.70 | CNR2 (0.45) | — | |
| SCHEMBL20858055 | 0.68 | AR (0.33) | ARCHEK1 | |
| SCHEMBL2616418 | 0.66 | CCR9 (0.43) | HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL17806570 | 0.65 | KIF11 (0.56) | ARALDH1A1HPGDSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669239-B2 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| US-20190337897-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337897-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | UTS2R, OPRL1, TRPV1 | PPARD 2535/4885AR 62/4885HTT 61/4885 |
| US-10669239-B2 | Tetrahydronaphthyl urea derivative | OPRL1, TRPV1, UTS2R | PPARD 2410/4885AR 73/4885HTT 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.